The FDA approved a bolus vial form of tirofiban hydrochloride (Aggrastat) on Sept. 1.
Medicure, which manufactures and markets tirofiban hydrochloride, said in a news release that the company developed the new product format after hearing from interventional cardiologists and catheterization laboratory nurses.
The new format is a concentrated, pre-mixed, 15 ml vial designed to deliver a 25 mcg/kg bolus dose of tirofiban hydrochloride. The drug will be available in the fourth quarter of this year, according to Medicure.
The FDA has approved tirofiban hydrochloride to reduce the combined endpoint of death, MI or refractory ischemia/repeat cardiac procedures in patients with non-ST elevation acute coronary syndrome.
Executive Editor
Tim Casey joined TriMed Media Group in 2015 as Executive Editor. For the previous four years, he worked as an editor and writer for HMP Communications, primarily focused on covering managed care issues and reporting from medical and health care conferences. He was also a staff reporter at the Sacramento Bee for more than four years covering professional, college and high school sports. He earned his undergraduate degree in psychology from the University of Notre Dame and his MBA degree from Georgetown University.